Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204239 | 0.91 | EGLN1 (0.83) | EGLN1ALDH1A1MAPT | |
| SCHEMBL12697382 | 0.88 | EGLN1 (0.79) | EGLN1ALDH1A1 | |
| SCHEMBL2201947 | 0.88 | EGLN1 (0.79) | EGLN1ALDH1A1MAPT | |
| SCHEMBL2202181 | 0.88 | EGLN1 (0.79) | EGLN1ALDH1A1 | |
| SCHEMBL2206131 | 0.88 | EGLN1 (1.00) | EGLN1ALDH1A1 | |
| SCHEMBL8310038 | 0.87 | EGLN1 (1.00) | EGLN1ALDH1A1 | |
| SCHEMBL6983554 | 0.86 | EGLN1 (0.76) | EGLN1MAPTNSD2MAPK8ATM | |
| SCHEMBL2144302 | 0.86 | EGLN1 (0.75) | EGLN1MAPTNSD2MAPK8ATM | |
| SCHEMBL2203862 | 0.85 | EGLN1 (0.74) | EGLN1ALDH1A1 | |
| SCHEMBL2201315 | 0.85 | EGLN1 (1.00) | EGLN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105168213-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA | 2015-12-23 | — | — | CN | claimed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | claimed |
| EP-2519503-B1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2013-10-23 | — | — | EP | claimed |
| US-20120329797-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2012-12-27 | — | — | US | claimed |
| EP-2519503-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM S.A. (LU) | 2012-11-07 | — | — | EP | claimed |
| CN-102712597-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives as antifungal agents | POLICHEM SA | 2012-10-03 | — | — | CN | claimed |
| EP-2345642-A1 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM S.A. (LU) | 2011-07-20 | — | — | EP | claimed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | claimed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| CN-105168213-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA | 2015-12-23 | — | — | CN | disclosed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | disclosed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | disclosed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | disclosed |
| EP-2519503-B1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2013-10-23 | — | — | EP | disclosed |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | ANTHONY NEVILLE J (US) | 2005-08-11 | — | — | US | disclosed |
| US-6921759-B2 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | EGLN1 2027/4885ALDH1A1 2855/4885MAPT 2944/4885 |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | EGLN1 2027/4885ALDH1A1 2855/4885MAPT 2944/4885 |
| US-20120329797-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | ERG28, TUBA8, CYP51A1 | EGLN1 1246/4885ALDH1A1 1232/4885MAPT 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.